Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

648P - An open-label, MRCT phase I/II study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of first-in-class bi-ligand-drug conjugate CBP-1019 in patients (pts) with advanced solid tumors

Date

14 Sep 2024

Session

Poster session 01

Topics

Clinical Research;  Targeted Therapy

Tumour Site

Gynaecological Malignancies

Presenters

Dan Liu

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

D. Liu1, L. Shen1, Y. Sun2, N. Li3, O. Marathe4, R. Huang5, J. Shao5, M. Xu6, B. Pan6, F. Pan5, S. Gao6, J. Gong1

Author affiliations

  • 1 Gastrointestinal Oncology, Peking University Cancer Hospital, 100142 - Beijing/CN
  • 2 Phase I Clinical Research Center, Shandong Cancer Hospital, 250117 - Jinan/CN
  • 3 Gcp Center, Cancer Hospital Chinese Academy of Medical Sciences, 100021 - Beijing/CN
  • 4 Department Of Oncology, TOI Clinical Research, Cerritos/US
  • 5 Clinical Development, Coherent Biopharma, 215123 - Suzhou/CN
  • 6 Clinical Development, Coherent Biopharma, 214024 - Suzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 648P

Background

CBP-1019 is a globally first-in-class bi-specific ligand drug conjugate (Bi-XDC) that targets both FRα and TRPV6 with the payload of exatecan (DX-8951), developed by Coherent Biopharma. Preclinical studies have shown that CBP-1019 with a MW of only 3 KD can deliver more payloads than TOPO-I ADCs with a favorable safety profile, demonstrating a therapeutic window of 15-30 folds greater. Up to 90%-100% TGI was observed in PDX models at the dose of 50-75 mg/kg (equivalent to 4 - 6 mg/kg in human). We designed a phase I/II study to evaluate the safety and efficacy of CBP-1019 in pts with advanced solid tumors (NCT05830097). Currently, we reported the results from the phase I study.

Methods

In phase I study, an accelerated titration design was employed for the first two dose levels (1.0, 2.0 mg/kg Q2W), followed by a standard "3+3” design for the subsequent dose levels (3.0 - 6.0 mg/kg Q2W). Dose expansion would be conducted in selected dose levels. The primary endpoints included safety, MTD, RP2D and ORR.

Results

By 31st Mar. 2024, 22 pts were enrolled (1.0 - 4.0 mg/kg), with median age of 59 years. All pts were heavily prior treated with median 4 lines of treatment. DLT was not observed and MTD not yet reached. Most TRAEs were grade 1 or 2. The most commonly ≥grade 3 TRAEs mainly in neutrophil count decreased (27.3%), platelet count decreased (18.2%), white blood cell count decreased (13.6%), anemia (9.1%) and lymphocyte count decreased (9.1%). 4 pts have been treated for over 4 months (the longest treatment duration is over 7 months) without AEs of interstitial pneumonia or ophthalmic toxicity occurred. Among 13 efficacy evaluable pts ≥ 2.0 mg/kg dose, 2 ovarian cancer pts with confirmed PR (maximum target lesion reduction was 66.0% and 34.0%, respectively) and 9 with SD were observed. The exposure of CBP-1019 and DX-8951 increased with dose escalation, without accumulation of either substance after multiple doses.

Conclusions

CBP-1019 as the first-in-class bi-XDC globally, was well-tolerated at 1.0 - 4.0 mg/kg Q2W without DLTs or other common severe toxicities observed in ADCs. Preliminary antitumor activity was seen at ≥2 mg/kg dose.

Clinical trial identification

NCT05830097.

Editorial acknowledgement

Legal entity responsible for the study

Coherent Biopharma.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.